Analisis Polimorfisme Genetik sebagai Prediktor Respons Imun dan Efektivitas Terapi Standar pada Pasien Diabetes Melitus Tipe 2

Authors

  • Novycha Auliafendri Universitas Imelda Medan
  • Alex Handani Sinaga Universitas Imelda Medan

DOI:

https://doi.org/10.55123/insologi.v4i5.6488

Keywords:

Type 2 Diabetes Mellitus, Genetic Polymorphism, IL-6, HbA1c, Combination Therapy

Abstract

Type 2 diabetes mellitus (T2DM) is a chronic disease with high prevalence and significant public health impact. This study aimed to analyze the association of IL-6 gene polymorphism (−174G>C) with serum IL-6 levels and the effectiveness of standard therapy assessed through HbA1c and Random Blood Glucose (RBG) in T2DM patients. A cross-sectional design was employed, involving 40 patients at Imelda Hospital. The polymorphism was examined using Polymerase Chain Reaction (PCR), serum IL-6 levels were measured with Enzyme-Linked Immunosorbent Assay (ELISA), while HbA1c and RBG were determined through standard laboratory analysis. The results indicated that IL-6 genotypes (GG, GC, CC) were not significantly associated with serum IL-6 levels, HbA1c, or RBG. In contrast, type of therapy showed a significant relationship with HbA1c, where patients receiving combination therapy achieved better glycemic control compared to those on monotherapy. These findings highlight that therapeutic regimen remains the primary determinant of glycemic control, whereas the role of IL-6 polymorphism in this study population appears limited. Further studies with larger sample sizes and broader genetic analyses are required to strengthen the application of precision medicine for diabetes management in Indonesia.

Downloads

Download data is not yet available.

References

Aboelkhair, N. T., Kasem, Heba Elsayed, Abdelmoaty, Amera Anwar, & Eledel, Rawhia Hassan. (2021). TCF7L2 Gene Polymorphism as a Risk for Type 2 Diabetes Mellitus and Diabetic Microvascular Complications. Molecular Biology Reports, 48, 5283–5290. https://doi.org/10.1007/s11033-021-06537-0

Ayelign, B., Negash, M., Andualem, H., Wondemagegn, T., Kassa, E., Shibabaw, T., Akalu, Y., & Molla, M. D. (2021). Association of IL-10 (− 1082 A/G) and IL-6 (− 174 G/C) gene polymorphism with type 2 diabetes mellitus in Ethiopia population. BMC Endocrine Disorders, 21(1), 70. https://doi.org/10.1186/s12902-021-00738-1

Berbudi, A., Khairani, S., & Tjahjadi, A. (2025). Interplay Between Insulin Resistance and Immune Dysregulation in Type 2 Diabetes Mellitus: Implications for Therapeutic Interventions. ImmunoTargets and Therapy, Volume 14, 359–382. https://doi.org/10.2147/ITT.S499605

Fathy, S. A., Mohamed, M. R., Ali, M. A. M., EL-Helaly, A. E., & Alattar, A. T. (2019). Influence of IL-6, IL-10, IFN-γ and TNF-α genetic variants on susceptibility to diabetic kidney disease in type 2 diabetes mellitus patients. Biomarkers, 24(1), 43–55. https://doi.org/10.1080/1354750X.2018.1501761

Fernández-Real, J. M., Broch, M., Vendrell, J., Gutiérrez, C., Casamitjana, R., Pugeat, M., Richart, C., & Ricart, W. (2000). Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes, 49(3), 517–520. https://doi.org/10.2337/diabetes.49.3.517

Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020). Pathophysiology of Type 2 Diabetes Mellitus. International Journal of Molecular Sciences, 21(17), 6275. https://doi.org/10.3390/ijms21176275

Guo, W., Song, Y., Sun, Y., Du, H., Cai, Y., You, Q., Fu, H., & Shao, L. (2022). Systemic immune-inflammation index is associated with diabetic kidney disease in Type 2 diabetes mellitus patients: Evidence from NHANES 2011-2018. Frontiers in Endocrinology, 13, 1071465. https://doi.org/10.3389/fendo.2022.1071465

Huang, Y., Huang, Q., Xu, A., Lu, M., & Xi, X. (2022). Patient Preferences for Diabetes Treatment Among People With Type 2 Diabetes Mellitus in China: A Discrete Choice Experiment. Frontiers in Public Health, 9, 782964. https://doi.org/10.3389/fpubh.2021.782964

International Diabetes Federation. (2021). IDF diabetes atlas (10th ed.). Brussels, Belgium: International Diabetes Federation. https://diabetesatlas.org

Kaaffah, S., Soewondo, P., Riyadina, W., Renaldi, F. S., & Sauriasari, R. (2021). Adherence to Treatment and Glycemic Control in Patients with Type 2 Diabetes Mellitus: A 4-Year Follow-up PTM Bogor Cohort Study, Indonesia. Patient Preference and Adherence, Volume 15, 2467–2477. https://doi.org/10.2147/PPA.S318790

Li, L.-J., Huang, L., Tobias, D. K., & Zhang, C. (2022). Gestational Diabetes Mellitus Among Asians – A Systematic Review From a Population Health Perspective. Frontiers in Endocrinology, 13, 840331. https://doi.org/10.3389/fendo.2022.840331

Martínez-Ramírez, O. C., Salazar-Piña, D. A., de Lorena, R.-G. M., Castro-Hernández, C., Casas-Ávila, L., Portillo-Jacobo, J. A., & Rubio, J. (2021). Association of NFκβ, TNFα, IL-6, IL-1β, and LPL Polymorphisms with Type 2 Diabetes Mellitus and Biochemical Parameters in a Mexican Population. Biochemical Genetics, 59(4), 940–965. https://doi.org/10.1007/s10528-021-10047-w

Muthoharoh, A., Safitri, W. A., Pambudi, D. B., & Rahman, F. (2020). Pola Pengobatan Antidiabetik Oral pada Pasien Diabetes Mellitus Tipe 2 Rawat Jalan di RSUD Kajen Pekalongan. Pharmacon: Jurnal Farmasi Indonesia, 29–36. https://doi.org/10.23917/pharmacon.v0i0.10841

Prasad, R., & Groop, L. (2015). Genetics of Type 2 Diabetes—Pitfalls and Possibilities. Genes, 6(1), 87–123. https://doi.org/10.3390/genes6010087

Ray, G. W., Zeng, Q., Kusi, P., Zhang, H., Shao, T., Yang, T., Wei, Y., Li, M., Che, X., & Guo, R. (2024). Genetic and inflammatory factors underlying gestational diabetes mellitus: A review. Frontiers in Endocrinology, 15, 1399694. https://doi.org/10.3389/fendo.2024.1399694

Suzuki, K., Hatzikotoulas, K., Southam, L., Taylor, H. J., Yin, X., Lorenz, K. M., Mandla, R., Huerta-Chagoya, A., Melloni, G. E. M., Kanoni, S., Rayner, N. W., Bocher, O., Arruda, A. L., Sonehara, K., Namba, S., Lee, S. S. K., Preuss, M. H., Petty, L. E., Schroeder, P., … Zeggini, E. (2024). Genetic drivers of heterogeneity in type 2 diabetes pathophysiology. Nature, 627(8003), 347–357. https://doi.org/10.1038/s41586-024-07019-6

Tian, X., Wang, L., Zhong, L., Zhang, K., Ge, X., Luo, Z., Zhai, X., & Liu, S. (2025). The research progress and future directions in the pathophysiological mechanisms of type 2 diabetes mellitus from the perspective of precision medicine. Frontiers in Medicine, 12, 1555077. https://doi.org/10.3389/fmed.2025.1555077

Yahaya, J. J., Doya, I. F., Morgan, E. D., Ngaiza, A. I., & Bintabara, D. (2023). Poor glycemic control and associated factors among patients with type 2 diabetes mellitus: A cross-sectional study. Scientific Reports, 13(1), 9673. https://doi.org/10.1038/s41598-023-36675-3

Downloads

Published

2025-10-15

How to Cite

Novycha Auliafendri, & Sinaga, A. H. (2025). Analisis Polimorfisme Genetik sebagai Prediktor Respons Imun dan Efektivitas Terapi Standar pada Pasien Diabetes Melitus Tipe 2. INSOLOGI: Jurnal Sains Dan Teknologi, 4(5), 1213–1225. https://doi.org/10.55123/insologi.v4i5.6488

Issue

Vol. 4 No. 5 (2025): Oktober 2025

Section

Articles

License

Copyright (c) 2025 Novycha Auliafendri, Alex Handani Sinaga

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Hak cipta pada setiap artikel adalah milik penulis.
Penulis mengakui bahwa INSOLOGI (Jurnal Sains dan Teknologi) sebagai publisher yang mempublikasikan pertama kali dengan lisensi Creative Commons Attribution 4.0 International License.
Penulis dapat memasukan tulisan secara terpisah, mengatur distribusi non-ekskulif dari naskah yang telah terbit di jurnal ini kedalam versi yang lain, seperti: dikirim ke respository institusi penulis, publikasi kedalam buku, dan lain-lain. Dengan mengakui bahwa naskah telah terbit pertama kali pada INSOLOGI (Jurnal Sains dan Teknologi).